Policy & Regulation
Sangamo Therapeutics anticipates USD200.0m from planned public offering of common stock
25 April 2018 -

Genomic therapy company Sangamo Therapeutics Inc (Nasdaq:SGMO) disclosed on Tuesday the start of its public offering of USD200.0m common stock.

The company plans to provide the underwriters of the offering with a 30-day option to purchase up to an additional USD30.0m of shares of its common stock solely to cover overallotments at the public offering price, less the underwriting discounts and commissions.

Net proceeds may be used by the company to support its own and its partnered gene therapy, genome editing, cell therapy, gene regulation product candidates, research programmes, for its manufacturing facilities, other business development activities, general corporate purposes and working capital.

BofA Merrill Lynch, JP Morgan Securities LLC and Cowen and Company LLC are acting as joint book-running managers for the offering.

Subject to market and other conditions, there can be no assurance as to whether or when the offering will be completed, or as to the actual size or terms.